ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

INO Inovio Pharmaceuticals Inc New

10.22
0.13 (1.29%)
Last Updated: 15:26:35
Delayed by 15 minutes
Share Name Share Symbol Market Type
Inovio Pharmaceuticals Inc New NASDAQ:INO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.13 1.29% 10.22 10.21 10.28 10.2772 10.0201 10.09 43,872 15:26:35

INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023

26/07/2023 2:32pm

PR Newswire (US)


Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart


From Jun 2023 to Jun 2024

Click Here for more Inovio Pharmaceuticals Charts.

PLYMOUTH MEETING, Pa., July 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that second quarter 2023 financial results will be released after the market close on August 9, 2023. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update.

A live and archived version of the audio presentation will be available online at http://ir.inovio.com/events-and-presentations/default.aspx. This is a listen-only event but will include a live Q&A with analysts.

About INOVIO

INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases. INOVIO's DNA medicines in development are delivered using its investigational proprietary smart device, CELLECTRA®, to produce immune responses against targeted pathogens and cancers. For more information, visit www.inovio.com.

Contacts

Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267) 440-4298 thomas.hong@inovio.com

 

Cision View original content:https://www.prnewswire.com/news-releases/inovio-to-report-second-quarter-2023-financial-results-on-august-9-2023-301886336.html

SOURCE INOVIO Pharmaceuticals, Inc.

Copyright 2023 PR Newswire

1 Year Inovio Pharmaceuticals Chart

1 Year Inovio Pharmaceuticals Chart

1 Month Inovio Pharmaceuticals Chart

1 Month Inovio Pharmaceuticals Chart